Journal
HEPATOLOGY
Volume 60, Issue 5, Pages 1776-1782Publisher
WILEY
DOI: 10.1002/hep.27246
Keywords
-
Categories
Funding
- National Institutes of Health [P01-CA080124, R01-CA159258, R21-CA139168]
- National Cancer Institute/Proton Beam Federal Share Program award
- American Cancer Society [120733-RSG-11-073-01-TBG]
- Astellas Foundation for Research on Metabolic Disorders, Japan
Ask authors/readers for more resources
Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available